Axsome Therapeutics, Inc. (AXSM) Financials
AXSM Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 713.6 million | 659.0 million |
| Dec. 31, 2025 | 689.8 million | 601.5 million |
| Sept. 30, 2025 | 669.3 million | 595.5 million |
| June 30, 2025 | 639.8 million | 566.7 million |
AXSM Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | -20.8 million | 23.4 million |
| Dec. 31, 2025 | -18.7 million | 22.7 million |
| Sept. 30, 2025 | 988000 | 23.1 million |
| June 30, 2025 | -32.4 million | 24.6 million |
AXSM Net Income
No data available :(
AXSM Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 305.1 million | 146.1 million | 32.1 million |
| Dec. 31, 2025 | 322.9 million | 140.9 million | 27.4 million |
| Sept. 30, 2025 | 325.3 million | 117.6 million | 27.7 million |
| June 30, 2025 | 303.0 million | 117.5 million | 29.8 million |
AXSM Shares Outstanding
AXSM Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 121000 | 52.7 million | 185.0 million | - |
| Dec. 31, 2025 | 71000 | 48.8 million | 169.3 million | - |
| Sept. 30, 2025 | 58000 | 40.2 million | 150.2 million | 41.4 million |
| June 30, 2025 | 13000 | 49.5 million | 130.3 million | 36.0 million |
AXSM Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | 191.2 million | 14.7 million |
| Dec. 31, 2025 | 196.0 million | 12.3 million |
| Sept. 30, 2025 | 171.0 million | 11.9 million |
| June 30, 2025 | 150.0 million | 13.4 million |
AXSM Revenue by Segment
Graph available only for paid members. Upgrade to see it.
AXSM
Price: $235
52 week price:
Earnings Per Share: -3.72 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.9 million
Ebitda: -6.3 millionMarket Capitalization: 11.2 billion